Amgen and Horizon argue FTC's suit to block $28B merger is 'as misguided as it is unprecedented'
Amgen and Horizon Therapeutics argued on Friday that the Federal Trade Commission’s bundling claims are a “square peg in a round hole.”
The FTC …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
